Tanimoto Keiji, Hizuka Naomi, Fukuda Izumi, Takano Kazue, Hanafusa Toshiaki
Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan.
Eur J Endocrinol. 2008 Oct;159(4):375-9. doi: 10.1530/EJE-08-0243. Epub 2008 Jul 24.
The purpose of this study was to investigate the influence of age on GH and IGF1 axis, and complications in patients with acromegaly.
From the medical records, we retrospectively analyzed clinical features and complications in 87 newly diagnosed patients with active acromegaly (34 males, 53 females; aged 18-82 years) who were admitted to Tokyo Women's Medical University between 1999 and 2006. We divided the patients into three groups according to age: <or=30 years old (young group), 31-60 years old (middle-aged group), and >or=61 years old (elderly group).
The median GH levels in young, middle-aged, and elderly groups were 18.5, 8.8, and 6.7 microg/l respectively, and the IGF1 levels were 810, 717, and 740 microg/l respectively. The values were not significantly different among the groups. However, the serum IGF1 SDS were significantly higher in the elderly group (10.2) than those in young and middle-aged groups (6.6 and 6.2 respectively, P<0.001). The age difference in the higher IGF1 SDS was remarkable in female patients. In the elderly group, glucose intolerance and hypertension were found in 94 and 53% of the patients respectively and the incidences were higher than those in the other groups.
This study suggests that the relatively high IGF1 secretions in elderly patients might be involved in the progression of clinical complications in acromegalic patients. Therefore, awareness of the early symptoms and examination of serum GH and IGF1 are important for patients with acromegaly.
本研究旨在调查年龄对肢端肥大症患者生长激素(GH)和胰岛素样生长因子1(IGF1)轴的影响以及并发症情况。
我们从病历中回顾性分析了1999年至2006年期间入住东京女子医科大学的87例新诊断的活动性肢端肥大症患者(男性34例,女性53例;年龄18 - 82岁)的临床特征和并发症。我们根据年龄将患者分为三组:≤30岁(年轻组)、31 - 60岁(中年组)和≥61岁(老年组)。
年轻组、中年组和老年组的GH水平中位数分别为18.5、8.8和6.7微克/升,IGF1水平分别为810、717和740微克/升。各组间这些值无显著差异。然而,老年组的血清IGF1标准差积分(SDS)显著高于年轻组和中年组(分别为10.2、6.6和6.2,P<0.001)。较高的IGF1 SDS在女性患者中的年龄差异尤为明显。在老年组中,分别有94%和53%的患者出现糖耐量异常和高血压,其发生率高于其他组。
本研究表明老年患者相对较高的IGF1分泌可能与肢端肥大症患者临床并发症的进展有关。因此,对肢端肥大症患者而言,了解早期症状以及检测血清GH和IGF1很重要。